Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 630 across all filing types
Latest filing 2021-04-28 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
成都先导药物开发股份有限公司2020年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage and actual use of funds raised by the company Chengdu Lead Drug Development Co., Ltd. for the year 2020. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange regarding the management and use of raised funds. The document includes specifics on the amount raised, usage, storage, investment projects, and audit opinions from Deloitte Huayong CPA and the sponsoring institution. The content focuses on the management and use of capital raised through an IPO and related financial activities, which aligns with a Capital/Financing Update. It is not a full annual report or earnings release, nor is it a simple announcement or certification. The length and detail confirm it is a substantive report on capital usage rather than a brief announcement or regulatory filing. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-04-28 Chinese
成都先导药物开发股份有限公司关于使用部分暂时闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Chengdu Lead Drug Development Co., Ltd. regarding the use of temporarily idle self-owned funds for cash management. It details the amount, purpose, types of financial products, authorization, risk control measures, and opinions from independent directors and the supervisory board. The document is a formal announcement about financing activities related to cash management and investment of idle funds, not a financial report or earnings release. It does not contain financial statements or detailed financial results but rather informs shareholders and the market about the company's capital management plans and approvals. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 2395 characters, which is typical for an announcement rather than a full report.
2021-04-28 Chinese
成都先导药物开发股份有限公司2020年年度报告
Annual Report Classification · 100% confidence The document is titled '2020 年年度报告' which translates to '2020 Annual Report'. It contains detailed sections typical of an annual report such as company overview, financial data for the year 2020, risk disclosures, governance, and audited financial statements. It mentions the audit firm Deloitte Hua Yong and includes comprehensive financial figures, business summaries, and management discussions. The length is substantial (15,000 characters) and it is not a brief announcement or a certification. Therefore, this document is the full official yearly report covering company activity and full financial performance for the fiscal year 2020, fitting the definition of an Annual Report (10-K). FY 2020
2021-04-28 Chinese
成都先导药物开发股份有限公司2020年年度利润分配预案公告
Notice of Dividend Amount Classification · 95% confidence The document is a profit distribution plan announcement for the year 2020 by Chengdu Lead Drug Development Co., Ltd. It details the proposed cash dividend per share, the total amount to be distributed, and the approval process including board and supervisory opinions. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution proposal and related procedural approvals. It is an announcement of the dividend amount and payment plan rather than a full annual report or earnings release. Therefore, it fits the category of Notice of Dividend Amount (DIV). The document length is short (1668 characters), consistent with a dividend announcement rather than a full report.
2021-04-28 Chinese
成都先导药物开发股份有限公司关于公司变更会计政策的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from the board of Chengdu Lead Drug Development Co., Ltd. regarding a change in accounting policy related to the adoption of a new lease accounting standard issued by the Ministry of Finance of China. It explains the nature of the accounting policy change, its implementation date (January 1, 2021), and its expected impact on the company's financial statements. The document is relatively short (1430 characters) and serves as a formal notification of the accounting policy change rather than a full financial report or audit report. It does not contain detailed financial statements or comprehensive analysis but rather informs stakeholders about the policy update and compliance with new accounting standards. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-04-28 Chinese
中国国际金融股份有限公司关于成都先导药物开发股份有限公司2020年度募集资金存放与使用情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report on the 2020 annual use and storage of funds raised by Chengdu Lead Drug Development Co., Ltd. It includes specifics on the amount raised, usage, management, and regulatory compliance of the raised funds. It also contains audit opinions from accounting firms and the sponsor institution's verification. The content focuses on the special verification of the use and storage of raised funds for the year 2020, which aligns with a specialized audit or verification report rather than a full annual report or earnings release. The document is lengthy (15,000 characters) and contains substantive financial and compliance data, not just an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR), which covers standalone audit reports and results of regulatory checks on specific financial matters such as raised funds usage. FY 2020
2021-04-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.